| Literature DB >> 35000018 |
Eita Uchida1,2, Atsushi Sasaki3, Mitsuaki Shirahata4, Tomonari Suzuki4, Jun-Ichi Adachi4, Kazuhiko Mishima4, Masanori Yasuda5, Takamitsu Fujimaki6, Koichi Ichimura7,8, Ryo Nishikawa4.
Abstract
Pineal parenchymal tumors (PPTs) are clinically rare and a biopsy is often required for a definitive diagnosis. To improve the accuracy of histological assessment of PPTs, we examined the proliferative capacity of PPT cells and investigated DICER1 expression and KBTBD4 mutations. This study included 19 cases of PPTs [3 pineocytomas (PCs), 10 PPTs of intermediate differentiation (PPTID), and 6 pineoblastomas (PBs)]. Immunohistochemistry for Ki-67, PHH3, and DICER1, as well as Sanger sequencing analysis for KBTBD4 mutations, was performed using formalin-fixed paraffin-embedded tissue specimens that were resected during surgery. Tumor cell proliferation was quantified using an image analysis software. For the PHH3 and MIB-1 indices, a significant difference was observed between the PPTIDs and PBs (P < 0.05). Loss of DICER1 was not specific for PB; 0/3 PCs (0.0%), 2/9 PPTIDs (22.2%), and 2/4 PBs (50.0%). KBTBD4 mutations were detected in 1/3 PCs (33.3%), 6/9 PPTIDs (66.7%), and 0/4 PBs (0.0%). Thus, combined application of the proliferative marker index and KBTBD4 mutation analysis may be useful for the differential diagnosis of PPTs. Furthermore, detection of KBTBD4 mutations using Sanger sequencing analysis may support the diagnosis of PPTID.Entities:
Keywords: Differential diagnosis; KBTBD4 mutation; MIB-1; PHH3; Pineal parenchymal tumor
Mesh:
Substances:
Year: 2022 PMID: 35000018 DOI: 10.1007/s10014-021-00421-2
Source DB: PubMed Journal: Brain Tumor Pathol ISSN: 1433-7398 Impact factor: 3.298